Tci Wealth Advisors, Inc. Vertex Pharmaceuticals Inc Transaction History

Tci Wealth Advisors, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 03, 2023	BUY	$283.23 - $323.1 $1,132 - $1,292	4 Added 2.23%	183 $57,000
Q4 2022 Feb 06, 2023	BUY	$285.76 - $321.48 $9,430 - $10,608	33 Added 22.6%	179 $51,000
Q3 2022 Nov 08, 2022	BUY	$273.83 - $305.53 $5,750 - $6,416	21 Added 16.8%	146 $42,000
Q1 2022 Apr 29, 2022	BUY	$221.42 - $260.97 $442 - $521	2 Added 1.63%	125 $33,000
Q4 2021 Jan 24, 2022	BUY	$177.01 - $223.45 $6,903 - $8,714	39 Added 46.43%	123 $27,000
Q3 2021 Oct 29, 2021	BUY	$181.39 - $202.99 $3,446 - $3,856	19 Added 29.23%	84 $15,000
Q2 2021 Aug 02, 2021	SELL	$187.49 - $221.1 $12,936 - $15,255	-69 Reduced 51.49%	65 $13,000
Q1 2021 Apr 29, 2021	BUY	$207.02 - $241.31 $25,670 - $29,922	124 Added 1240.0%	134 $29,000
Q1 2020 Apr 14, 2020	SELL	$199.77 - $247.81 $5,993 - $7,434	-30 Reduced 75.0%	10 $2,000
Q4 2019 Jan 27, 2020	BUY	$166.71 - $223.91 $1,667 - $2,239	10 Added 33.33%	40 $9,000
Q2 2018 Jul 27, 2018	BUY	$145.72 - $169.96 $2,914 - $3,399	20 Added 200.0%	30 $5,000
Q2 2017 Aug 10, 2017	BUY	N/A	10	10 $1,000

1,723

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Tci Wealth Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Tci Wealth Advisors, Inc. with notifications on news.